cytarabine has been researched along with vosaroxin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arbitrario, JP; Fox, JA; Hawtin, RE; Howlett, AR; Kumer, JL; Scatena, CD; Silverman, JA | 1 |
| Burnett, AK; Coles, SJ; Knapper, S; Walsby, EJ | 1 |
| Feldman, EJ | 1 |
| Chen, T; Craig, AR; Cripe, LD; Fox, JA; Hawtin, R; Karp, JE; Lancet, JE; Leavitt, RD; Maris, MB; Michelson, GC; Ravandi, F; Roboz, GJ; Stuart, RK | 1 |
| Burnett, AK; Clark, RE; Dennis, M; Dignum, H; Hemmaway, C; Hills, RK; Kjeldsen, L; McMullin, MF; Milligan, D; Panoskaltsis, N; Russell, N; Thomas, IF | 1 |
| Hotinski, AK; Lewis, ID; Ross, DM | 1 |
| Acton, G; Carella, AM; Cortes, J; Craig, AR; Craig, MD; Damon, L; Derigs, HG; Erba, HP; Fox, JA; Gaidano, G; Havelange, V; Heuser, M; Hogge, D; Horst, HA; Jabbour, E; Kantarjian, HM; Klimek, VM; Lancet, JE; Maertens, J; Mehta, C; Odenike, O; Pigneux, A; Powell, BL; Ravandi, F; Recher, C; Ritchie, EK; Roboz, GJ; Sayar, H; Schiller, GJ; Smith, JA; Strickland, SA; Stuart, RK; Thomas, X; Vey, N; Ward, R; Wei, A | 1 |
| Fox, JA; Jamieson, GC; Poi, M; Strickland, SA | 1 |
| Acton, G; Carella, AM; Cortes, JE; Craig, AR; Craig, MD; Egyed, M; Fox, JA; Horst, HA; Jabbour, E; Kantarjian, HM; Klimek, VM; Krug, U; Lancet, JE; Pigneux, A; Ravandi, F; Récher, C; Ritchie, EK; Sayar, H; Schiller, GJ; Smith, JA; Strickland, SA; Stuart, RK; Vey, N; Ward, R | 1 |
| Che, F; Gui, C; Huang, J; Wang, C; Zhang, L | 1 |
3 review(s) available for cytarabine and vosaroxin
| Article | Year |
|---|---|
Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Naphthyridines; Recurrence; Thiazoles; Topoisomerase Inhibitors; Treatment Failure | 2015 |
Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Haplorhini; Humans; Leukemia, Myeloid, Acute; Mice; Middle Aged; Naphthyridines; Quinolones; Rats; Thiazoles | 2016 |
A Bayesian Network Meta-Analysis Comparing the Efficacies of Eleven Novel Therapies with the Common Salvage Regimen for Relapsed or Refractory Acute Myeloid Leukemia.
Topics: Bayes Theorem; Cytarabine; Disease-Free Survival; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Naphthyridines; Neoplasm Recurrence, Local; Odds Ratio; Pyrazoles; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Thiazoles | 2018 |
4 trial(s) available for cytarabine and vosaroxin
| Article | Year |
|---|---|
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Naphthyridines; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Salvage Therapy; Survival Rate; Thiazoles; Young Adult | 2015 |
Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthyridines; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Remission Induction; Survival Rate; Thiazoles | 2015 |
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthyridines; Neoplasm Recurrence, Local; Remission Induction; Thiazoles; Treatment Outcome | 2015 |
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthyridines; Recurrence; Thiazoles | 2018 |
3 other study(ies) available for cytarabine and vosaroxin
| Article | Year |
|---|---|
Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Bone Marrow Cells; Cell Proliferation; Cytarabine; Disease Models, Animal; Drug Synergism; Female; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Leukocytes; Mice; Naphthyridines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thiazoles | 2010 |
The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine.
Topics: Apoptosis; Cell Culture Techniques; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytarabine; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Deletion; Genes, p53; Humans; Lethal Dose 50; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Cells; Naphthyridines; Thiazoles; Topoisomerase II Inhibitors | 2011 |
Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?
Topics: Adenine; Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Cytarabine; Cytogenetics; Female; Germany; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Naphthalimides; Naphthyridines; Organophosphonates; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thiazoles | 2011 |